A citation-based method for searching scientific literature

Alexandra Leary, David Tan, Jonathan Ledermann. Ther Adv Med Oncol 2021
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Current developments in cancer vaccines and cellular immunotherapy.
Antoni Ribas, Lisa H Butterfield, John A Glaspy, James S Economou. J Clin Oncol 2003
222
100

PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
Jianfeng Shen, Wei Zhao, Zhenlin Ju, Lulu Wang, Yang Peng, Marilyne Labrie, Timothy A Yap, Gordon B Mills, Guang Peng. Cancer Res 2019
171
100

A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study.
Roisin E O'Cearbhaill, Wei Deng, Lee-May Chen, Joseph A Lucci, Kian Behbakht, Nick M Spirtos, Carolyn Y Muller, Benedict B Benigno, Matthew A Powell, Emily Berry,[...]. Gynecol Oncol 2019
8
100

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Mary L Disis, Matthew H Taylor, Karen Kelly, J Thaddeus Beck, Michael Gordon, Kathleen M Moore, Manish R Patel, Jorge Chaves, Haeseong Park, Alain C Mita,[...]. JAMA Oncol 2019
151
100

Checkpoint-inhibition in ovarian cancer: rising star or just a dream?
Klaus Pietzner, Sara Nasser, Sara Alavi, Silvia Darb-Esfahani, Mona Passler, Mustafa Zelal Muallem, Jalid Sehouli. J Gynecol Oncol 2018
21
100

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
Panagiotis A Konstantinopoulos, Steven Waggoner, Gregory A Vidal, Monica Mita, John W Moroney, Robert Holloway, Linda Van Le, Jasgit C Sachdev, Eloise Chapman-Davis, Gerardo Colon-Otero,[...]. JAMA Oncol 2019
149
100

Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.
Jonathan Oh, Minal Barve, Carolyn M Matthews, E Colin Koon, Thomas P Heffernan, Bruce Fine, Elizabeth Grosen, Melanie K Bergman, Evelyn L Fleming, Leslie R DeMars,[...]. Gynecol Oncol 2016
48
100

Spontaneous Regression of Ovarian Carcinoma After Septic Peritonitis; A Unique Case Report.
Thijs Roelofsen, Christina Wefers, Mark A J Gorris, Johannes C Textor, Leon F A G Massuger, I Jolanda M de Vries, Anne M van Altena. Front Oncol 2018
3
100

Pretreatment lymphocytopenia is an adverse prognostic biomarker in advanced-stage ovarian cancer.
Yong Jae Lee, Young Shin Chung, Jung-Yun Lee, Eun Ji Nam, Sang Wun Kim, Sunghoon Kim, Young Tae Kim. Cancer Med 2019
5
100


Clinical model: interferons activate human monocytes to an eradicative tumor cell level in vitro.
Samuel Baron, Jessica Hernandez, Joseph Bekisz, Joyce Poast, Neil Goldman, Kathleen Clouse, Karen Fields, Sylvia Bacot, Jiun Wang, Kathryn Zoon. J Interferon Cytokine Res 2007
11
100

Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising?
Antonio González-Martín, Luisa Sánchez-Lorenzo. Cancer 2019
20
100

Tumour-intrinsic resistance to immune checkpoint blockade.
Anusha Kalbasi, Antoni Ribas. Nat Rev Immunol 2020
257
100

Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression.
Brooke E Howitt, Kyle C Strickland, Lynette M Sholl, Scott Rodig, Lauren L Ritterhouse, Dipanjan Chowdhury, Alan D D'Andrea, Ursula A Matulonis, Panagiotis A Konstantinopoulos. Oncoimmunology 2017
57
100


A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D.
Jung Yun Lee, Jae Weon Kim, Myong Cheol Lim, Sunghoon Kim, Hee Seung Kim, Chel Hun Choi, Ju Yeon Yi, Sang Yoon Park, Byoung Gie Kim. J Gynecol Oncol 2019
7
100


Ovarian cancer stem cells more questions than answers.
Petronella Beatrix Ottevanger. Semin Cancer Biol 2017
54
100

Adoptive cell therapy with tumor-infiltrating lymphocytes in patients with metastatic ovarian cancer: a pilot study.
Magnus Pedersen, Marie Christine Wulff Westergaard, Katy Milne, Morten Nielsen, Troels Holz Borch, Lars Grønlund Poulsen, Helle Westergren Hendel, Mia Kennedy, Gillian Briggs, Stacey Ledoux,[...]. Oncoimmunology 2018
39
100

Interleukin‑33 expression in ovarian cancer and its possible suppression of peritoneal carcinomatosis.
Atsushi Sekiya, Shiro Suzuki, Ayako Tanaka, Satomi Hattori, Yusuke Shimizu, Nobuhisa Yoshikawa, Yoshihiro Koya, Hiroaki Kajiyama, Fumitaka Kikkawa. Int J Oncol 2019
5
100

Correction to: "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up".
A Vogel, A Cervantes, I Chau, B Daniele, J M Llovet, T Meyer, J-C Nault, U Neumann, J Ricke, B Sangro,[...]. Ann Oncol 2019
21
100

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
D Planchard, S Popat, K Kerr, S Novello, E F Smit, C Faivre-Finn, T S Mok, M Reck, P E Van Schil, M D Hellmann,[...]. Ann Oncol 2018
500
100

Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Eric Pujade-Lauraine, Keiichi Fujiwara, Jonathan A Ledermann, Amit M Oza, Rebecca Kristeleit, Isabelle-Laure Ray-Coquard, Gary E Richardson, Cristiana Sessa, Kan Yonemori, Susana Banerjee,[...]. Lancet Oncol 2021
9
100


Near eradication of clinically relevant concentrations of human tumor cells by interferon-activated monocytes in vitro.
Samuel Baron, Joel Finbloom, Julie Horowitz, Joseph Bekisz, Angel Morrow, Tongmao Zhao, Samuel Fey, Hana Schmeisser, Corey Balinsky, Kotaro Miyake,[...]. J Interferon Cytokine Res 2011
10
100


Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
J A Ledermann, F A Raja, C Fotopoulou, A Gonzalez-Martin, N Colombo, C Sessa. Ann Oncol 2013
402
100

Cancers Related to Immunodeficiencies: Update and Perspectives.
Esmaeil Mortaz, Payam Tabarsi, Davod Mansouri, Adnan Khosravi, Johan Garssen, Aliakbar Velayati, Ian M Adcock. Front Immunol 2016
74
100

Opportunities in immunotherapy of ovarian cancer.
G Coukos, J Tanyi, L E Kandalaft. Ann Oncol 2016
36
100

Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.
G J Freeman, A J Long, Y Iwai, K Bourque, T Chernova, H Nishimura, L J Fitz, N Malenkovich, T Okazaki, M C Byrne,[...]. J Exp Med 2000
100

Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer.
Wenying Yan, Hongmei Hu, Biao Tang. Onco Targets Ther 2019
16
100

Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study.
Dmitriy Zamarin, Robert A Burger, Michael W Sill, Daniel J Powell, Heather A Lankes, Michael D Feldman, Oliver Zivanovic, Camille Gunderson, Emily Ko, Cara Mathews,[...]. J Clin Oncol 2020
67
100

Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.
Suzanne L Topalian, Janis M Taube, Robert A Anders, Drew M Pardoll. Nat Rev Cancer 2016
100

Epidemiology of ovarian cancer: a review.
Brett M Reid, Jennifer B Permuth, Thomas A Sellers. Cancer Biol Med 2017
468
100

Pembrolizumab in patients with programmed death ligand 1-positive advanced ovarian cancer: Analysis of KEYNOTE-028.
Andrea Varga, Sarina Piha-Paul, Patrick A Ott, Janice M Mehnert, Dominique Berton-Rigaud, Anne Morosky, Ping Yang, Jane Ruman, Daniela Matei. Gynecol Oncol 2019
89
100


Antigen-Presenting Cell-Intrinsic PD-1 Neutralizes PD-L1 in cis to Attenuate PD-1 Signaling in T Cells.
Yunlong Zhao, Devin L Harrison, Yuran Song, Jie Ji, Jun Huang, Enfu Hui. Cell Rep 2018
69
100

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.
Lin Zhang, Jose R Conejo-Garcia, Dionyssios Katsaros, Phyllis A Gimotty, Marco Massobrio, Giorgia Regnani, Antonis Makrigiannakis, Heidi Gray, Katia Schlienger, Michael N Liebman,[...]. N Engl J Med 2003
100

Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis.
Wei-Ting Hwang, Sarah F Adams, Emin Tahirovic, Ian S Hagemann, George Coukos. Gynecol Oncol 2012
366
100

Current status and development of anti-PD-1/PD-L1 immunotherapy for lung cancer.
Luyao Wang, Qingxia Ma, Ruixue Yao, Jia Liu. Int Immunopharmacol 2020
19
100

Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and PD-ligand- 1 (PD-L1) in ovarian cancer.
Maureen L Drakes, Swati Mehrotra, Monica Aldulescu, Ronald K Potkul, Yueying Liu, Anne Grisoli, Cara Joyce, Timothy E O'Brien, M Sharon Stack, Patrick J Stiff. J Ovarian Res 2018
36
100

Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial.
R S Freedman, C L Edwards, J J Kavanagh, A P Kudelka, R L Katz, C H Carrasco, E N Atkinson, W Scott, B Tomasovic, S Templin. J Immunother Emphasis Tumor Immunol 1994
91
100

Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
David D Bowtell, Steffen Böhm, Ahmed A Ahmed, Paul-Joseph Aspuria, Robert C Bast, Valerie Beral, Jonathan S Berek, Michael J Birrer, Sarah Blagden, Michael A Bookman,[...]. Nat Rev Cancer 2015
510
100

CAR-T cell therapy in ovarian cancer: from the bench to the bedside.
Xinxin Zhu, Han Cai, Ling Zhao, Li Ning, Jinghe Lang. Oncotarget 2017
26
100

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice.
H Nishimura, T Okazaki, Y Tanaka, K Nakatani, M Hara, A Matsumori, S Sasayama, A Mizoguchi, H Hiai, N Minato,[...]. Science 2001
100

Breast Cancer Immunotherapy: Facts and Hopes.
Leisha A Emens. Clin Cancer Res 2018
207
100

A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron® (Peginterferon alfa-2b) and Actimmune® (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer.
Daniel S Green, Ana T Nunes, Virginia David-Ocampo, Irene B Ekwede, Nicole D Houston, Steven L Highfill, Hanh Khuu, David F Stroncek, Seth M Steinberg, Kathryn C Zoon,[...]. J Transl Med 2018
11
100


Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment.
Veronica Rojas, Kim M Hirshfield, Shridar Ganesan, Lorna Rodriguez-Rodriguez. Int J Mol Sci 2016
86
100

Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA).
Junzo Hamanishi, Nobuhiro Takeshima, Noriyuki Katsumata, Kimio Ushijima, Tadashi Kimura, Satoshi Takeuchi, Koji Matsumoto, Kimihiko Ito, Masaki Mandai, Hidekatsu Nakai,[...]. J Clin Oncol 2021
3
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.